# Zhejiang Cuize Pharmaceutical Technology Co., Ltd.: Phase 3 study in Hemorrhoids Second Degree, Hemorrhoids Third Degree (243 participants)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Zhejiang Cuize Pharmaceutical Technology Co., Ltd. |
| Sponsor type | Academic and hospital |
| Study | A Clinical Trial of Local Infiltration With Injection CZ1S for Postoperative Analgesia After Hemorrhoidectomy |
| NCT ID | NCT07909902 |
| Phase | Phase 3 |
| Status | completed |
| Conditions | Hemorrhoids Second Degree; Hemorrhoids Third Degree; Analgesia |
| Intervention types | drug |
| Target enrollment | 243 |
| Site countries | China |
| Posted | 2026-11-02 |
| Planned start | 2025-05-21 |
| Event | Newly registered study |
| Event date | 2026-11-02 |

## Why this score
- Posted in the last two weeks.
- Phase 3: multi-site, larger budget.
- 243 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07909902). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.